Skip to main content
. Author manuscript; available in PMC: 2024 May 1.
Published in final edited form as: Lancet Oncol. 2023 May;24(5):509–522. doi: 10.1016/S1470-2045(23)00112-2

Table 2.

Treatment Emergent Adverse Events (TEAE) per patient (N = 17 patients, >10% of patients (and all grade ≥ 3 AE), all cycles) sequence in order of frequency.

Treatment Emergent Adverse Events (TEAE)
AE All Grades Grade 1-2 Grade 3 Grade 4
Anemia 15 (88.24%) 15 (88.24%) 0 (0%) 0 (0%)
Headache 15 (88.24%) 15 (88.24%) 0 (0%) 0 (0%)
Leukopenia 15 (88.24%) 10 (58.82%) 5 (29.41%) 0 (0%)
Hypertension 14 (82.35%) 9 (52.94%) 5 (29.41%) 0 (0%)
Lymphopenia 14 (82.35%) 11 (64.71%) 3 (17.65%) 0 (0%)
Hyperglycemia 12 (70.59%) 12 (70.59%) 0 (0%) 0 (0%)
Neutropenia 12 (70.59%) 4 (23.53%) 7 (41.18%) 1 (5.88%)
Fatigue 11 (64.71%) 10 (58.82%) 1 (5.88%) 0 (0%)
Seizure 8 (47.06%) 5 (29.41%) 3 (17.65%) 0 (0%)
Bradycardia 8 (47.06%) 8 (47.06%) 0 (0%) 0 (0%)
Alopecia 7 (41.18%) 7 (41.18%) 0 (0%) 0 (0%)
Dysphasia 7 (41.18%) 6 (35.29%) 1 (5.88%) 0 (0%)
Nausea 7 (41.18%) 7 (41.18%) 0 (0%) 0 (0%)
ALAT increased 6 (35.29%) 6 (35.29%) 0 (0%) 0 (0%)
ASAT increased 6 (35.29%) 6 (35.29%) 0 (0%) 0 (0%)
CNS abnormality,
other		 6 (35.29%) 6 (35.29%) 0 (0%) 0 (0%)
Thrombocytopenia 6 (35.29%) 6 (35.29%) 0 (0%) 0 (0%)
Scalp pain 6 (35.29%) 6 (35.29%) 0 (0%) 0 (0%)
Blurred vision 5 (29.41%) 5 (29.41%) 0 (0%) 0 (0%)
Dysesthesia 5 (29.41%) 5 (29.41%) 0 (0%) 0 (0%)
Insomnia 4 (23.53%) 4 (23.53%) 0 (0%) 0 (0%)
Muscle weakness
upper limb		 4 (23.53%) 4 (23.53%) 0 (0%) 0 (0%)
Sinus tachycardia 4 (23.53%) 4 (23.53%) 0 (0%) 0 (0%)
Weight loss 4 (23.53%) 4 (23.53%) 0 (0%) 0 (0%)
Alkaline phosphatase
↑		 3 (17.65%) 3 (17.65%) 0 (0%) 0 (0%)
Anorexia 3 (17.65%) 3 (17.65%) 0 (0%) 0 (0%)
Dizziness 3 (17.65%) 3 (17.65%) 0 (0%) 0 (0%)
Facial muscle
weakness		 3 (17.65%) 3 (17.65%) 0 (0%) 0 (0%)
Arthralgia 2 (11.76%) 2 (11.76%) 0 (0%) 0 (0%)
Cognitive disturbance 2 (11.76%) 2 (11.76%) 0 (0%) 0 (0%)
Depression 2 (11.76%) 2 (11.76%) 0 (0%) 0 (0%)
Dysarthria 2 (11.76%) 2 (11.76%) 0 (0%) 0 (0%)
Encephalopathy 2 (11.76%) 1 (5.88%) 1 (5.88%) 0 (0%)
Fever 2 (11.76%) 2 (11.76%) 0 (0%) 0 (0%)
Hypercalcemia 2 (11.76%) 2 (11.76%) 0 (0%) 0 (0%)
Hypokalemia 2 (11.76%) 2 (11.76%) 0 (0%) 0 (0%)
Hyponatremia 2 (11.76%) 2 (11.76%) 0 (0%) 0 (0%)
Hypophosphatemia 2 (11.76%) 2 (11.76%) 0 (0%) 0 (0%)
Memory impairment 2 (11.76%) 2 (11.76%) 0 (0%) 0 (0%)
Optic nerve disorder 2 (11.76%) 2 (11.76%) 0 (0%) 0 (0%)
Paresthesia 2 (11.76%) 2 (11.76%) 0 (0%) 0 (0%)
Somnolence 2 (11.76%) 2 (11.76%) 0 (0%) 0 (0%)